Testing effectiveness (Phase 2)Not Yet RecruitingNCT07589595
What this trial is testing
Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
Who this might be right for
Cognitive DysfunctionLewy Body DiseaseSynucleinopathies+1 more
Eli Lilly and Company 350